Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
11 2022
Historique:
received: 29 06 2022
revised: 14 07 2022
accepted: 16 07 2022
pubmed: 26 7 2022
medline: 8 11 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Hepatic chronic graft-versus-host disease (cGVHD) causes morbidity and current diagnostic criteria are nonspecific. An accurate diagnosis is imperative because overdiagnosis can lead to unnecessary treatment with immunosuppressive agents and raising the risk of opportunistic infections. We aim to characterize different patterns of liver injury and cytokine profiles associated with hepatic dysfunction in cGVHD, to evaluate the accuracy of the NIH Consensus Criteria (NCC) for hepatic cGVHD and to explore predictors for hepatic cGHVD. Patients were evaluated in this prospective cross-sectional study of patients with cGVHD recruited under a natural history protocol. Laboratory tests and cytokines were measured. The cGVHD were diagnosed and scored based on NCC. Clinically indicated liver biopsy specimens or autopsies were reviewed by an expert hepatopathologist (D.E.K.). Comparisons were made between groups, and univariable and multivariable logistic regression were calculated. Of the 302 patients enrolled, 151 fulfilled hepatic cGVHD based on NCC; however, 69% had at least 1 abnormal liver test result. Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase were associated with lower platelets, higher total bilirubin (TB), total cholesterol, serum amyloid A, and IL 15. Abnormal ALP and gamma-glutamyl transpeptidase were associated with higher cholesterol, and IL7. Lower platelet count was associated with higher ALT, TB, and triglycerides and lower albumin. Of the 27 with liver tissue, 16 had histologic features of GVHD, only eight met clinical criteria for hepatic GVHD. Sensitivity and specificity of NCC in identifying hepatic GVHD were 50% and 27% (Kappa = -0.23). Only 6 had only hepatic GVHD, whereas 10 had hepatic GVHD with either iron overload, nodular regenerative hyperplasia, or steatosis. Multivariable logistic regression showed that ALP and total cholesterol were associated with hepatic GVHD and total cholesterol >220 mg/dL increased the sensitivity for histologic hepatic GVHD. In conclusion, abnormal liver enzymes in cGVHD are nonspecific and have poor correlation with histologic evidence for hepatic GVHD, highlighting the importance of histology. Cytokines provide insight into the pathogenesis of hepatic cGVHD. Decreased platelet count was associated with factors associated with liver disease including portal vein diameter, which may suggest progression of liver disease. This highlights the need of incorporating these factors in natural history study and using liver biopsy to understand the development of liver dysfunction in hematopoietic stem cell transplantation and to develop better instruments to decreased hepatic cGVHD related morbidity and mortality. The study was registered with a ClinicalTrials.gov identifier NCT00092235.

Identifiants

pubmed: 35878742
pii: S2666-6367(22)01478-6
doi: 10.1016/j.jtct.2022.07.017
pmc: PMC10707451
mid: NIHMS1825529
pii:
doi:

Substances chimiques

Cytokines 0
Cholesterol 97C5T2UQ7J

Banques de données

ClinicalTrials.gov
['NCT00092235']

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

747.e1-747.e10

Subventions

Organisme : Intramural NIH HHS
ID : ZIA BC011743
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA DK075008
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Références

Blood. 1989 Sep;74(4):1428-35
pubmed: 2670000
N Engl J Med. 2010 Dec 30;363(27):2600-10
pubmed: 21190454
Bone Marrow Transplant. 2010 Oct;45(10):1546-52
pubmed: 20190846
Biol Blood Marrow Transplant. 2011 Feb;17(2):167-75
pubmed: 20691801
Biol Blood Marrow Transplant. 2012 Aug;18(8):1174-81
pubmed: 22664751
Leuk Lymphoma. 2014 Jun;55(6):1350-6
pubmed: 24024470
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Bone Marrow Transplant. 2011 Oct;46(10):1374-81
pubmed: 21132028
Hepatology. 2000 Dec;32(6):1265-71
pubmed: 11093733
Eur Cytokine Netw. 2010 Sep;21(3):186-94
pubmed: 20736143
Gene. 2016 May 25;583(1):48-57
pubmed: 26945629
Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63
pubmed: 24447907
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Bone Marrow Transplant. 2001 Dec;28(11):1047-51
pubmed: 11781615
J Biol Chem. 2015 May 15;290(20):12804-11
pubmed: 25847238
Br J Haematol. 2012 Jul;158(1):46-61
pubmed: 22533811
J Clin Oncol. 2008 Dec 10;26(35):5735-41
pubmed: 19001329
APMIS. 1991 Jul;99(7):674-6
pubmed: 2069809
Leukemia. 2012 Apr;26(4):633-43
pubmed: 22005783
PLoS One. 2015 Apr 09;10(4):e0122026
pubmed: 25856141
Biol Blood Marrow Transplant. 2015 May;21(5):780-92
pubmed: 25644957
Bone Marrow Transplant. 2014 Jul;49(7):972-6
pubmed: 24777193
Biol Blood Marrow Transplant. 2015 Apr;21(4):589-603
pubmed: 25639770
Clin Transplant. 2012 Mar-Apr;26(2):E168-75
pubmed: 22507357
Blood. 2011 Oct 20;118(16):4472-9
pubmed: 21878671
J Clin Pathol. 1992 Apr;45(4):348-51
pubmed: 1577974
Transplantation. 1998 Oct 15;66(7):863-71
pubmed: 9798695
Nat Rev Immunol. 2007 May;7(5):340-52
pubmed: 17438575
Hepatology. 1988 May-Jun;8(3):463-70
pubmed: 3131226
Autoimmun Rev. 2006 Jan;5(1):1-9
pubmed: 16338205
Rejuvenation Res. 2009 Oct;12(5):311-20
pubmed: 19725773
Best Pract Res Clin Haematol. 2008 Jun;21(2):101-17
pubmed: 18503979
Bone Marrow Transplant. 2009 Dec;44(11):729-37
pubmed: 19398965
Bone Marrow Transplant. 2005 Jan;35(1):85-9
pubmed: 15531904
Biol Blood Marrow Transplant. 2007 Oct;13(10):1207-15
pubmed: 17889358
Hepatology. 2009 Dec;50(6):1809-17
pubmed: 19821522
Am J Respir Cell Mol Biol. 1991 Aug;5(2):155-62
pubmed: 1892646
Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59
pubmed: 25985921
Exp Mol Pathol. 2014 Dec;97(3):338-44
pubmed: 25217811
Semin Hematol. 2012 Jan;49(1):35-42
pubmed: 22221783
Hepatology. 2005 Feb;41(2):345-52
pubmed: 15660388
Gastroenterology. 2008 Jun;134(7):1917-26
pubmed: 18439425
N Engl J Med. 1991 Apr 4;324(14):933-40
pubmed: 1900574
Blood. 2011 Oct 13;118(15):4250-7
pubmed: 21791415
Nat Rev Immunol. 2012 May 11;12(6):443-58
pubmed: 22576252
Transplant Proc. 1974 Dec;6(4):367-71
pubmed: 4155153
J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S88-91
pubmed: 16958682

Auteurs

Alexander H Yang (AH)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Ma Ai Thanda Han (MAT)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Niharika Samala (N)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Bisharah S Rizvi (BS)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Rachel Marchalik (R)

National Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.

Ohad Etzion (O)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Elizabeth C Wright (EC)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of the Director, Bethesda, Maryland.

Liang Cao (L)

National Cancer Institute (NCI), Center for Cancer Research, Genetics Branch, Bethesda, Maryland.

Frances T Hakim (FT)

National Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.

Elizabeth Jones (E)

National Cancer Institute (NCI) Radiology and Imaging Services, Bethesda, Maryland.

Devika Kapuria (D)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Dennis D Hickstein (DD)

National Cancer Institute (NCI), Immune Deficiency Cellular Therapy Program, Bethesda, Maryland.

Daniel Fowler (D)

Rapa Therapeutics, Rockville, Maryland.

Jennifer A Kanakry (JA)

National Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.

Christopher G Kanakry (CG)

National Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.

David E Kleiner (DE)

National Cancer Institute (NCI), Laboratory of Pathology, Bethesda, Maryland.

Christopher Koh (C)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.

Steven Z Pavletic (SZ)

National Cancer Institute (NCI) Radiology and Imaging Services, Bethesda, Maryland.

Theo Heller (T)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland. Electronic address: theoh@intra.niddk.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH